Loading

Please wait...

Crysvita

Generic Name: burosumab (bur OH sue mab)
Brand Name: Crysvita
Physician reviewed Crysvita patient information - includes Crysvita description, dosage and directions.
  • Prescription Settings

Prices and coupons of Crysvita

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Crysvita is a monoclonal antibody that targets and blocks the activity of a blood protein called FGF23. In a genetic condition called X-linked hypophosphatemia (HYE-poe-fos-fa-TEEM-ee-a), low phosphate levels in blood are caused by abnormally high levels of FGF23 protein, which causes the kidneys to stop reabsorbing phosphate into the bloodstream. Blocking the FGF23 protein allows the kidneys to restore and maintain normal phosphate levels. Phosphate is important for the strength of your bones and teeth. Low phosphate levels can lead to bone deformities and growth problems. Learn more

Crysvita Side Effects

Crysvita Side Effects

Note: This document contains side effect information about burosumab. Some of the dosage forms listed on this page may not apply to the brand name Crysvita.

For the Consumer

Applies to burosumab: subcutaneous solution

Along with its needed effects, burosumab (the active ingredient contained in Crysvita) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking burosumab:

More common

  • Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • bone malformations
  • confusion
  • difficulty in breathing
  • fast heartbeat
  • fever
  • frequent bone fractures
  • hives, itching, skin rash
  • hoarseness
  • irregular heartbeat
  • irritation
  • joint pain, stiffness, or swelling
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • numbness and tingling around the mouth, fingertips, or feet
  • pain in the arm or leg
  • redness of the skin
  • seizures
  • slowed growth
  • stomach cramps
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • tremor
  • troubled breathing or swallowing

Some side effects of burosumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Aching or discomfort in the lower legs or sensation of crawling in the legs
  • back pain
  • constipation
  • difficulty in moving
  • dizziness
  • headache
  • muscle ache, cramp, pain, or stiffness
  • toothache
  • vomiting

For Healthcare Professionals

Applies to burosumab: subcutaneous solution

General

The most commonly reported adverse reactions in pediatric patients have included injection site reactions, vomiting, pyrexia, and extremity pain. In adult patients, back pain, tooth infection, restless leg syndrome, dizziness, and constipation have been reported. In both adults and pediatric patients, headache and decreased vitamin D has been reported.

Metabolic

Increased blood phosphorus was reported in 6% of adult patients during clinical trials. There were no reports of increased blood phosphorus in pediatric clinical trials.

Very common (10% or more): Vitamin D decreased (up to 37%)

Common (1% to 10%): Blood phosphorus increased

Gastrointestinal

Very common (10% or more): Vomiting (up to 48%), toothache (up to 23%), tooth abscess (up to 23%)

Common (1% to 10%): Constipation

Hypersensitivity

In pediatric patients, the more frequent events that were considered potential hypersensitivity events included rash (22%), injection site rash (6%), and urticaria (5%). In adult patients approximately 6% of patients in both the study group and placebo group experience mild or moderate hypersensitivity reactions that did not require drug discontinuation.

Frequency not reported: Hypersensitivity reactions

Dermatologic

Very common (10% or more): Rash (up to 27%)

Rash includes pruritic, maculopapular, and pustular rashes

Musculoskeletal

Spinal stenosis is common in adults with X-linked hypophosphatemia (XLH). In phase 2/3 studies, 6 patients (n=176) underwent spinal surgery for what appeared to involve progression of a preexisting spinal stenosis. It is unknown if therapy exacerbates spinal stenosis or spinal cord compression.

Very common (10% or more): Extremity pain (up to 46%), myalgia (up to 17%), back pain (15%)

Common (1% to 10%): Spinal surgery

Other

Very common (10% or more): Pyrexia (up to 48%)

Local

Injection site reactions have included erythema, pruritus, swelling, pain, rash, bruising, discoloration, discomfort, hematoma, hemorrhage, induration, macule, and urticaria at the injection site

Very common (10% or more): Injection site reaction (up to 67%)

Nervous system

Very common (10% or more): Headache (up to 73%), dizziness (up to 15%), restless leg syndrome (12%)

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Crysvita